

25 November 2025

Osteopore strikes 5 year partnership with DKSH for dental product distribution in Malaysia

Highlights

- Osteopore strikes a 5-year partnership with DKSH Malaysia Sdn Bhd, subsidiary of DKSH Holding Ltd (SIX:DKSH) for the distribution of its dental products in Malaysia.
- This partnership aims to establish Osteopore's dental products as the new gold standard in Guided Bone Regeneration, targeting between 20-30% Compound Annual Growth Rate (CAGR) over the first five years.
- The key target customers are Malaysian oral maxillofacial surgeons, prosthodontists, and periodontists in private practice.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX:OSX; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce a five year partnership with DKSH Malaysia Sdn Bhd, a subsidiary of DKSH Holding Ltd (SIX:DKSH), for the distribution of its dental products, Osteomesh® and Osteoplug®, in Malaysia.

The dental products covered in this partnership are off-the-shelf products designed to assist in a surgical procedure known as Guided Bone Regeneration (GBR) where a combination of membrane, bone grafts, and/or bone substitutes are used to encourage new bone growth in areas where there is insufficient bone volume.



Based on a market research report¹, the Malaysian GBR and Guided Tissue Regeneration market is projected to reach around USD\$60 million by 2028 with a CAGR of 6.3%. Growth drivers include medical tourism and increasing awareness of periodontal health. Bioresorbable membranes and enhanced regenerative materials are also reported to be gaining traction in Malaysia.

Based on in-market research, Osteopore and DKSH Malaysia will focus on oral maxillofacial surgeons, prosthodontists, and periodontists, who are practicing predominantly in the major cities of Selangor and Kuala Lumpur, Johor, and Penang.

Osteopore and DKSH Malaysia aim to triple the number of products currently supplied in the first year of partnership and become the new gold standard in Guided Bone Regeneration. Osteopore and DKSH Malaysia are committed to driving strong and sustainable growth for the brand, supported by increasing clinical adoption and expanding market reach nationwide.

This commercial collaboration builds on the prospective post-market clinical study in collaboration with Universiti Malaya (UM)² that has recently commenced. In the study, Osteopore's polycaprolactone membrane is being compared against collagen membrane, and is led by oral maxillofacial surgeon Dr. Tan Chuey Chuan from the Department of Oral and Maxillofacial Clinical Sciences at UM.

Summary of key commercial terms:

- **Terms of Agreement:** Initial term of five (5) years and two months or until 30 December 2030;
- **Products:** Osteomesh® and Osteoplug® for use in dental surgery

¹ Market Research Intellect, "Guided Tissue Regeneration Gtr Membrane Market by Applications: Malaysia, Germany, Japan, Canada, Hong Kong", 9 September 2025.

² ASX Announcement, "OSX & Universiti Malaya initiate dental bone healing trial", 8 August 2025.



Commenting on the partnership with DKSH Malaysia, CEO Dr Yujing Lim, said:

"We are glad to have secured a partnership with DKSH Malaysia shortly after the clinical study has commenced. With local clinical data being generated by the leading research university hospital in Malaysia, we can expect to leverage the clinical outcomes to support in-market adoption.

"As we continue to realign and strengthen our sales and distribution channels in a progressive and organised manner, we look forward to a strong partnership with DKSH Malaysia to introduce a technology that is experiencing growing traction in the country", said Dr Lim.

Commenting on the partnership with Osteopore, Sandeep Tewari, Vice President, Healthcare at DKSH Malaysia , said:

"Osteopore's technology has the potential to be first-in-class in Malaysia, and we are excited to support the launch of this innovative solution and to make it accessible to healthcare professionals and patients across the market.

"Clinicians within our network have expressed strong interest in Osteopore's products, especially when bone regrowth and augmentation are required. This partnership reinforces DKSH's commitment to enriching people's lives and providing healthcare for all by delivering advanced medical innovations that elevate the standard of care across Malaysia", said Sandeep.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com



About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

About DKSH

For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,940 specialists, the Business Unit generated net sales of CHF 5.7 billion in 2024. www.dksh.com/hec

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.



No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

